Masimo (MASI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$179.950.00%
Close 2026-06-10 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · MASI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 55.7% |
| Our one-year growth estimate | diamond | 0.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 55.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
MASI — director departure
Dated 2026-06-10
Catherine Szyman, Gregory Meehan, Charles Dadswell: Executives resigned their employment and board positions in connection with a Merger.
Why it matters: Finishing the acquisition will make Masimo a part of Danaher. This will change its operations.
Supportive ifThe deal will close. Masimo will join Danaher by the end of 2026.
Worry ifThe acquisition fails to close by the end of 2026.
Why it matters: Approvals are important to finish the merger. Delays can change the timeline.
Worry ifAll needed approvals are granted by the end of Q3 2026 without delays.
Less concerning ifIf approvals are delayed or denied, the merger timeline will be pushed back.
Why it matters: Growing revenue is key for Masimo's money health and trust from investors.
Supportive ifQ2 2026 revenue growth meets or beats the target of about $1,523 million.
Worry ifQ2 2026 revenue growth is less than the target of about $1,523 million.
Why it matters: Revenue growth below 10% would signal a slowdown in the company's performance. This could impact investor confidence.
Worry ifQ3 revenue growth reported below 10% year over year.
Less concerning ifQ3 revenue growth remains at or above 10% year over year.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$8 on $10,000 · ±0.1% | How much price usually moves either way. |
| Bad day | $243 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,226 loss on $10,000 · 22.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing the merger will show Masimo's new path with Danaher.
Supportive ifThe acquisition is officially completed by the end of Q4 2026.
Worry ifThe acquisition is delayed beyond Q4 2026.
Why it matters: Leadership changes can affect the company's plans and how well it operates.
Worry ifNew leaders are chosen who improve the company's strategy.
Less concerning ifMore leaders are leaving. This causes instability in the company.
Why it matters: Delays may show financial problems. This could hurt investor trust.
Worry ifThe Credit Agreement ends without any delays.
Less concerning ifDelays or problems happen when ending the Credit Agreement.
Why it matters: Higher gross profit margins show better cost control and profit. This may help investor feelings.
Supportive ifGross profit margins are higher than last quarter.
Worry ifGross profit margins decline or remain flat compared to the previous quarter.
Why it matters: Better margins mean better cost control. This is important for making money long-term.
Supportive ifGross profit margins reported above the previous $250.8M in the next earnings report.
Worry ifGross profit margins decline or stay below $250.8M, indicating cost issues.
Why it matters: Maintaining strong revenue growth supports Masimo's growth strategy. It shows the company is on track.
Supportive ifRevenue reported above $403.6M in the next earnings report.
Worry ifRevenue below $372M shows growth is slowing down.
Why it matters: A drop in sector growth could impact Masimo's performance. It signals broader industry challenges.
Worry ifSector revenue growth below average shows a slowdown.
Less concerning ifSector revenue growth stays steady or gets better, helping Masimo grow.
Why it matters: Stable leaders help keep focus during the change.
Worry ifNo more leaders leave after the merger.
Less concerning ifMore key leaders leave after the merger.
Why it matters: Revenue growth trends will indicate if Masimo can meet its growth targets post-merger.
Supportive ifQ2 2026 revenue shows growth of at least 9% year over year.
Worry ifQ2 2026 revenue declines or grows less than 9% year over year.
Why it matters: New leaders can change company strategy and actions after the merger.
Watch forNew leaders are chosen who share Danaher's vision for Masimo.
Also watch forNo new executive appointments are made, and existing leaders remain in place.
Why it matters: Revenue growth will show if the company is doing well after the acquisition.
Watch forRevenue growth rate exceeds 9% year-over-year in Q2 2026.
Also watch forRevenue growth rate falls below 5% year-over-year in Q2 2026.
Why it matters: Approval is needed to finalize the merger. Delays could impact Masimo's growth plans.
Supportive ifApproval is given by the right government groups before the closing date.
Worry ifApproval is denied or delayed past the expected time.
Why it matters: Approvals are important to finish the merger. Delays could hurt Masimo's future.
Supportive ifAll needed approvals are granted on time.
Worry ifAny big delay or denial of approvals happens.
Why it matters: Revenue trends will show how well Masimo adapts to the merger with Danaher.
Supportive ifQ2 revenue grows compared to Q1, showing good integration.
Worry ifQ2 revenue drops compared to Q1, showing problems with integration.